NASDAQ:BNGO
Bionano Genomics, Inc.
Bionano Genomics, Inc.'s revenue fell 7.4% in fiscal 2025 to $28.5M while operating margin rose to −116.9%, its highest in 9 years. The diluted share count rose 328.4%.Summary generated from Bionano Genomics, Inc.'s SEC filings. Latest annual report filed Mar 23, 2026.
Key statistics
Fiscal 2025 from SEC filings. MethodologyRevenue (FY25)$28.5M
Revenue growth−7.4%
Revenue, 5-yr CAGR+27.4%
Gross margin46.3%
Operating margin−116.9%
Net margin−92.6%
ROICn/a
Return on equity−66.2%
Debt / equityn/a
Free cash flown/a
FCF marginn/a
Share count change+328.4%
Financials
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 18 | 28 | 36 | 31 | 29 |
| Operating income | −77 | −132 | −215 | −104 | −33 |
| Net income | −72 | −133 | −232 | −112 | −26 |
| Free cash flow | n/a | n/a | n/a | n/a | n/a |
Recent filings
- 8-KRegulation FD disclosure
Sep 14, 2026 - 4Insider transaction report
Sep 9, 2026 - 4Insider transaction report
Aug 21, 2026 - 10-QQuarterly report for the period ended Jun 30, 2026
Aug 10, 2026 - 8-KResults of operations and financial condition
Aug 10, 2026 - 8-KOther events
Jun 24, 2026 - 8-KDirector or officer change
Jun 5, 2026 - 8-KOther events
May 28, 2026